APPROVAL OF COVID-19 RELATED MEDICINES UNDER AYUSH

Print

CONTEXT: Government of India has released “National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19” prepared by the National Task force in consensus from various expert committees.

Analysis:

• Government of India has released “National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19” prepared by the National Task force in consensus from various expert committees.
• AYUSH-64 and Kabasur Kudineer has been identified for Covid-19 treatment. It was observed that AYUSH-64 as adjunct treatment to Standard Care resulted in significant improvement in clinical recovery. AYUSH 64 is also recommended in “National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19” prepared by National Task Force in consensus from various expert committees.
• Further, Kabasur Kudineer, a siddha preparation was also subjected to clinical trials for studying the efficacy in Covid-19 patients by Central Council for Research in Siddha (CCRS) under Ministry of Ayush and is also found useful in the treatment of mild to moderate covid-19 infection.
• A nationwide campaign has been undertaken for distribution of AYUSH-64 and Kabasura Kudineer through the Research Councils and the National Institutes under the Ministry of Ayush across the country.
• The Ministry of AYUSH has constituted an Interdisciplinary Technical Review Committee (ITRC).So far, the following applications have been approved in the ITRC with respect to COVID-19 claims: –
• Divya Coronil tablet of Patanjali Research Foundation Trust, Haridwar, Uttarakhand- recommended as supporting measure in the management of COVID-19 without claiming cure.
• Clevira Tablet of M/s Apex Laboratories Private Ltd., Tamilnadu has been recommended as a supporting measure for mild to moderate condition of COVID-19.
• Kabasura Kudineer of Sri Sri Tattva, Sriveda Sattva Pvt. Ltd., Bangalore has been recommended as an intervention for prevention and mild to moderate symptoms of COVID-19.

Reference: PIB